List view / Grid view
Antibiotic resistance is one of the key health challenges of the future. In a new study, researchers have carried out a multi-step analysis to deliver insights into translocation of the hydrophobic and hydrophilic portions of the large lipopolysaccharide molecules through the outer membrane of Neisseria gonorrhoeae. This article summarises their…
A new photonic effect in semiconducting helical particles with nanoscale dimensions has been discovered by an international team of scientists from the University of Bath, UK and the University of Michigan, US. Here, Professors Nicholas Kotov and Ventsislav Valev discuss their study and the observed effect which has the potential…
Drug testing on advanced cell-based models such as organoids has gained in popularity, but significant technical hurdles remain that prevent further assay miniaturisation and higher assay throughput. Through the replacement of animal-derived basement membranes with wood-derived nanofibrillar cellulose hydrogel (NFC), Dr Tijmen Booij and Dr Christian Stirnimann from ETH Zurich,…
Dr Erik Vernet, Director of Antibody Technology at Novo Nordisk, discusses antibody discovery and development workflows, including the role of informatics processes, in this Q&A.
Viral vectors to deliver gene therapies are utilised by clinically approved therapies. However, this method is not the only option for advanced therapeutics. In this piece, Brent Warner, President, Gene Therapy at Poseida Therapeutics, discusses the balance between efficacy and safety in gene therapy, highlighting positive pre-clinical data for non-viral…
Expectations are growing worldwide for discoveries that will harness the potential of cell therapy, which has already brought breakthroughs in therapeutic areas where there is an unmet need, from oncology to ophthalmology and rare disease. In this article, Dr Terri Gaskell, Chief Technology Officer at Rinri Therapeutics, explores some of…
While the full potential of gene therapies continues to be realised, their successes in rare diseases promote them as a promising treatment modality. Dr Gaurav Shah, Chief Executive Officer of Rocket Pharmaceuticals discusses the future of gene therapies as well as the company’s progress in in vivo and ex vivo programmes.
In this article, Dr Mary Spellman, Chief Medical Officer and Senior Vice President of R&D at Castle Creek Biosciences, discusses how a versatile dual platform of ex vivo and in vivo gene therapy technologies is being utilised for the development of novel gene therapies for a broad range of rare…
Dr Richard Goodwin, Head of Imaging & AI, Clinical Pharmacology & Safety Sciences at AstraZeneca, explores the latest innovation in early therapeutic development – spatial biology.
This ebook includes a piece by Daniel Morales- Mantilla, Dr Robin Parihar and Dr Katherine King, from Baylor College of Medicine, on a stem and progenitor cell infusion to improve the survival of mice from sepsis as well as an article by Dr Karen Litwa, East Carolina University, that explores…
In this section, Dr Peter O’Toole, University of York, examines innovation in the field of microscopy for drug discovery and development research, while in an exclusive Q&A, Dr Michael Grange, Rosalind Franklin Institute, discusses the advantages of utilising cryo-electron tomography imaging.
This ebook features insights into the discovery of a new non-linear chiroptical effect for characterising nanohelices in miniscule volumes, and a novel organoid drug-screening platform with numerous eco benefits.
This ebook features articles from gene therapy specialists that look at current platforms as well as the future of promising modalities for gene therapies. It also tackles novel stem cell technology considerations and gives insight into the careful balancing act between efficacy and safety in gene therapy.
In this issue are articles focusing on a novel stem cell therapy for hearing loss, how a non-linear chiroptical effect could aid drug discovery and the advantages of cryo-electron tomography for imaging research. Also included are pieces on gene therapy, spheroids and genomics.
Dr Owen Seddon, University Hospital of Wales, looks at how lessons learned during the pandemic can inform pre-clinical and early R&D phases of future vaccine work.
